Patrick Concannon, Ph.D.
Professor and Director, UF Genetics Institute | Pathology, Immunology and Laboratory Medicine
Ph.D. University of California, Los Angeles
Genetics, Genomic Technologies, Statistics, Immunologic Mechanisms
Dr. Patrick Concannon received his doctoral training at the University of California, Los Angeles and postdoctoral training at the California Institute of Technology. Prior to coming to UF, Dr. Concannon served as the associate director of the Center for Public Health Genomics, the Hanison professor of biochemistry and molecular genetics and a professor of hematology and oncology. Previously, he served as associate institute director and molecular genetics program director at the Benaroya Research Institute at Virginia Mason in Seattle. Supported by more than $12 million in grants from the National Institutes of Health, the Bill and Melinda Gates Foundation and the Juvenile Diabetes Research Foundation, Dr. Concannon’s work has led to more than 150 peer-reviewed papers in top journals, including Nature, the Journal of the American Medical Association, The New England Journal of Medicine and the Proceedings of the National Academy of Sciences. He has also authored more than 35 book chapters, reviews and invited publications, and given scores of invited presentations in many countries including Spain, Italy, Norway, Finland, Denmark, the Czech Republic, South Korea, Japan, Australia, Brazil, Canada, and the United States. In his current role as the UF Genetics Institute Director, Dr. Concannon works closely with researchers from the College of Medicine, the Institute of Food and Agricultural Sciences, and the College of Liberal Arts and Sciences to strengthen collaboration. The goal of those effmis will be greater cohesion among all the genetics-related activities at UF in medicine, agdculture, arts and sciences, pharmacology, veterinary medicine, dentistry and many other fields.
Key Research and Findings
Dr. Concannon is widely recognized for his work in genetic analysis of autoimmune diabetes, and, in addition, has made extensive contributions to other areas of translational medicine, including studies of DNA repair syndromes, TCR genetics, and fundamental immunology.
For more than 20 years, our studies of T1D have focused on defining the genetic risk factors that contribute to susceptibility to this disorder with the goals of better understanding the underlying pathology, and facilitating preventive approaches through early diagnosis and novel therapies. As a result of genome-wide association studies there are now more than 40 regions of the genome known to harbor genetic loci that increase risk for T1D. Our current studies are directed towards identifying the causative variants in these chromosomal regions, characterizing the effects of these variants on the relevant genes, and understanding how variation in the expression of these genes or the structure of their protein products impacts T1D pathology.
Additional publications can be found in PubMed.
- Teraoka SN, Bernstein JL, Reiner AS, Haile RW, Bernstein L, Lynch CF, Malone KE, Stovall M, Capanu M, Liang X, Smith SA, Mychaleckyj J, Hou X, Mellemkjaer L, Boice JD Jr, Siniard A, Duggan D, Thomas DC; The WECARE Study Collaborative Group, and Concannon P. (2011 ). Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women’s Environment, Cancer, and Radiation Epidemiology (WECARE) Study. Breast Cancer Res. 13:R114.
- Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L; The WECARE Study Collaborative Group,
Bernstein JL, Begg CB. (2012). Rare germline mutations in PALB2 and breast cancer risk: A population-based study. Hum Mutat. 33:674-680.
- Cooper JD, Howson JM, Smyth D, Walker NM, Stevens H, Yang JH, She JX, Eisenbarth GS, Rewers M, Todd JA, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Pociot F, Rich SS; the Type 1 Diabetes Genetics Consortium. (2012). Confirmation of novel type 1 diabetes risk loci in families.
- Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder, MJ, Tabor HK, Nickerson DA, Barnes KC; National Heart, Lung, and Blood
Institute (NHLBI) GO Exome Sequencing Project; Lung GO, Gibson RL, Bamshad MJ (2012). Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 44:886-9.
- Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d’lndy H, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, SantosCortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project, Jondeau G, Milewicz DM. (2012). TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 44:916-21.
- Howson JM, Cooper JD, Smyth DJ, Walker NM, Stevens H, She JX, Eisenbarth GS, Rewers M, Todd JA, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G,
Nerup J, Nierras C, Pociot F, Rich SS; and the Type 1 Diabetes Genetics Consortium. (2012). Evidence of Gene-Gene Interaction and Age-at-Diagnosis Effects in Type 1 Diabetes. Diabetes.
- Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker SJ, Day DB, Heneghan MA, Neuberger JM, Donaldson PT, Bathgate AJ, Burroughs A, Davies MH, Jones DE, Alexander GJ, Barrett JC; The UK Primary Biliary Cirrhosis (PBC) Consortium; The Wellcome Trust Case Control Consortium 3, Sandford RN,
Anderson CA. (20 12). Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat Genet. 44:1137-1141.
- Brooks JD, Bernstein L, Teraoka SN, Knight JA, Mellemkjaer L, John EM, Malone KE, Reiner AS, Lynch CF, Concannon P, Haile RW, Bernstein JL. (2012). Variation in
genes related to obesity, weight and weight change and risk of contralateral breast cancer in the WECARE